BioNTech signs agreement to acquire Biotheus
BioNTech has signed a definitive agreement to acquire Biotheus to obtain complete worldwide rights to BNT327/PM8002, a ...
BioNTech Acquires Biotheus to Enhance Cancer Therapies
BioNTech SE (BNTX) has released an update. BioNTech SE is set to acquire Biotheus in a deal valued at $800 million, aiming to strengthen its ...
Business Insider19h
BioNTech to acquire Biotheus for upfront consideration of $800M
In addition, BioNTech will gain a state-of-the-art biologics manufacturing facility to contribute to its future global manufacturing and supply, and more than 300 Biotheus employees in R&D, ...
Seeking Alpha23h
BioNTech to buy bispecific antibody developer Biotheus for up to $950M
BioNTech (BNTX) said the merger will strengthen its capabilities in developing, manufacturing and commercializing bispecific antibodies and treatment combinations. It will also expand the company’s ...